Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia

International Journal of Neuropsychopharmacology

Volumn 6, Issue 4, 2003, Pages 353-360

  Yamasue, Hidenori ^a,c   Fukui, Tsunehiro ^a   Fukuda, Rin ^a   Kasai, Kiyoto ^a   Iwanami, Akira ^a   Kato, Nobumasa ^a   Kato, Tadafumi ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

1H MR spectroscopy (1H MRS); Antipsychotics; Extrapyramidal side effects (EPS); Schizophrenia; Striatum

Indexed keywords

CHOLINE DERIVATIVE; CREATINE; CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION COEFFICIENT; DIAGNOSTIC IMAGING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IMAGE ANALYSIS; LONG TERM CARE; MALE; METABOLIC DISORDER; NEUROBIOLOGY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; SCHIZOPHRENIA; SCORING SYSTEM; SIMPSON ANGUS SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; BASAL GANGLIA DISEASES; CHOLINE; CHRONIC DISEASE; CREATINE; DOMINANCE, CEREBRAL; ENERGY METABOLISM; FEMALE; GLUTAMIC ACID; GLUTAMINE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE, SECONDARY; PHOSPHOCREATINE; PUTAMEN; REFERENCE VALUES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0742288284     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003687     Document Type: Article

References (32)

1. Abe K, Terakawa H, Takanashi M, Watanabe Y, Tanaka H, Fujita N, Hirabuki N, Yanagihara T (2000). Proton magnetic resonance spectroscopy of patients with parkinsonism. Brain Research Bulletin 52, 589-595.
2. Ando K, Takei N, Matsumoto H, Iyo M, Isoda H, Mori N (2002). Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. Schizophrenia Research 57, 273-279.
3. APA (1994). Diagnostic and Statistical Manual of Mental Disorder (4th edn). Washington, DC: American Psychiatric Association.
4. Barnes TR (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
5. Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, Breier A, Weinberger DR (1998). Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry 43, 641-648.
6. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, Weinberger DR (2001). The effect of treatment with antipsychotic drugs on brain N-acetyl-aspartate measures in patients with schizophrenia. Biological Psychiatry 49, 39-46.
7. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, Frank JA, Tedeschi G, Weinberger DR (1996). Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. American Journal of Psychiatry 153, 1554-1563.
8. Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL, Blanchard J, Keith SJ, Brooks WM (2001). Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Research 107, 135-149.
9. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC (1999). Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. American Journal of Psychiatry 156, 1200-1204.
10. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
11. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV Axis I Disorders: Clinical Version (SCID-CV). Washington, DC: American Psychiatric Association.
12. 1H-MRS and correlation with mental symptoms [in Japanese]. Tokyo: PhD thesis, University of Tokyo.
13. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF (2002). Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biological Psychiatry 51, 493-497.
14. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology (pp. 534-537). Washington, DC: US Department of Health, Education and Welfare. Publication ADM 76-338.
15. Hamakawa H, Kato T, Murashita J, Kato N (1998). Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. European Archives of Psychiatry and Clinical Neuroscience 248, 53-58.
16. Hamakawa H, Kato T, Shioiri T, Inubushi T, Kato N (1999). Quantitative proton magnetic resonance spectroscopy of the bilateral frontal lobes in patients with bipolar disorder. Psychological Medicine 29, 639-644.
17. Heimberg C, Komoroski RA, Lawson WB, Cardwell D, Karson CN (1998). Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Research 83, 105-115.
18. 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 50, 1033-1040.
19. Hollingshead AB (1965). Two-factor Index of Social Position. New Haven: Yale University Press.
20. Kane JM (2001). Extrapyramidal side effects are unacceptable. European Neuropsychopharmacology 11, S397-403.
21. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
22. Kerns JM, Sierens DK, Kao LC, Klawans HL, Carvey PM (1992). Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clinical Neuropharmacology 15, 488-500.
23. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW (1994). Changes in caudate volume with neuroleptic treatment. Lancet 344, 1434.
24. Meshul CK, Reassen OA (1996). Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology 125, 238-247.
25. Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J (1993). Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 187, 219-227.
26. Ohara K, Isoda H, Suzuki Y, Takehara Y, Ochiai M, Takeda H, Hattori K, Igarashi Y, Ohara K (2000). Proton magnetic resonance spectroscopy of lenticular nuclei in simple schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 24, 507-519.
27. Oldfield RC (1971). The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9, 97-113.
28. Pouwels PJ, Brockmann K, Kruse B, Wilken B, Wick M, Hanefeld F, Frahm J (1999). The regional age dependence of human brain metabolic from infancy to adulthood as detected by quantitative localized proton MRS. Pediatric Research 46, 474-485.
29. Shioiri T, Hamakawa H, Kato T, Murashita J, Fujii K, Inubushi T, Takahashi S (1996). Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: a preliminary report. Schizophrenia Research 22, 19-26.
30. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212 (Suppl.), 11-19.
31. Tarsy D, Baldessarini RJ, Tarazi FI (2002). Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16, 23-45.
32. 1H-MR-spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. NeuroReport 13, 2133-2137.